

# Antonio Aguilera Guirao

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/928433/antonio-aguilera-guirao-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62

papers

943

citations

17

h-index

27

g-index

70

ext. papers

1,106

ext. citations

4.3

avg, IF

3.34

L-index

#	Paper	IF	Citations
62	Considerations on HTLV-1 infection in Spain. <i>Medicina Clínica (English Edition)</i> , <b>2021</b> , 156, 578	0.3	
61	Considerations on HTLV-1 infection in Spain. <i>Medicina Clínica</i> , <b>2021</b> , 156, 578	1	
60	Hepatitis delta in patients hospitalized in Spain (1997-2018). <i>Aids</i> , <b>2021</b> , 35, 2311-2318	3.5	1
59	Usefulness of matrix-assisted laser desorption ionization/time of flight mass spectrometry for the identification of <i>Streptococcus mutans</i> . <i>Applied Microbiology and Biotechnology</i> , <b>2020</b> , 104, 10601-10612	5.7	
58	Hospital admissions in individuals with HTLV-1 infection in Spain. <i>Aids</i> , <b>2020</b> , 34, 1019-1027	3.5	6
57	The algorithm used for the interpretation of doravirine transmitted drug resistance strongly influences clinical practice and guideline recommendations. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 1294-1300	5.1	7
56	GEHEP 010 study: Prevalence and distribution of hepatitis B virus genotypes in Spain (2000-2016). <i>Journal of Infection</i> , <b>2020</b> , 81, 600-606	18.9	2
55	HIV co-infection in HTLV-1 carriers in Spain. <i>Virus Research</i> , <b>2019</b> , 266, 48-51	6.4	5
54	Surveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1693-1700	5.1	7
53	Comparative evaluation of the identification of rapidly growing non-tuberculous mycobacteria by mass spectrometry (MALDI-TOF MS), GenoType Mycobacterium CM/AS assay and partial sequencing of the <i>ropA</i> gene with phylogenetic analysis as a reference method. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2019</b> , 37, 160-166	0.9	4
52	HTLV-1 infection in solid organ transplant donors and recipients in Spain. <i>BMC Infectious Diseases</i> , <b>2019</b> , 19, 706	4	11
51	Ribavirin as a First Treatment Approach for Hepatitis E Virus Infection in Transplant Recipient Patients. <i>Microorganisms</i> , <b>2019</b> , 8,	4.9	2
50	Occult hepatitis B and HIV infection. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 1403-1407	2.2	8
49	Meningitis due to autochthonous acute infection with hepatitis E virus in a chef: a case report. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 1726-1728	5.1	2
48	Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2018</b> , 30, 1060-1062	2.2	11
47	Decline and changing profile of hepatitis delta among injection drug users in Spain. <i>Antiviral Therapy</i> , <b>2018</b> , 23, 87-90	1.6	5
46	HTLV infection in HCV-antibody positive patients in Spain. <i>AIDS Research and Human Retroviruses</i> , <b>2017</b> , 33, 1013-1017	1.6	

45	Human T-lymphotropic virus type 1 infection and disease in Spain. <i>Aids</i> , <b>2017</b> , 31, 1653-1663	3.5	20
44	Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. <i>Antiviral Therapy</i> , <b>2017</b> , 22, 307-312	1.6	45
43	Using NS5B Sequencing for Hepatitis C Virus Genotyping Reveals Discordances with Commercial Platforms. <i>PLoS ONE</i> , <b>2016</b> , 11, e0153754	3.7	32
42	Unexpected results in BK virus detection by real-time PCR due to polymorphisms in the T-antigen gene. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , <b>2015</b> , 33, 359-60	0.9	
41	Virological failure to raltegravir in Spain: incidence, prevalence and clinical consequences. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 3087-95	5.1	10
40	Molecular characterization of HIV-1 infection in Northwest Spain (2009-2013): Investigation of the subtype F outbreak. <i>Infection, Genetics and Evolution</i> , <b>2015</b> , 30, 96-101	4.5	18
39	The Burden of Neglected HIV-2 and HTLV-1 Infections in Spain. <i>AIDS Reviews</i> , <b>2015</b> , 17, 212-9	1.5	7
38	Molecular epidemiology and clinical features of human T cell lymphotropic virus type 1 infection in Spain. <i>AIDS Research and Human Retroviruses</i> , <b>2014</b> , 30, 856-62	1.6	8
37	Clinically relevant transmitted drug resistance to first line antiretroviral drugs and implications for recommendations. <i>PLoS ONE</i> , <b>2014</b> , 9, e90710	3.7	15
36	Very late HCV relapse following triple therapy for hepatitis C. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 723-4	1.6	4
35	X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. <i>Aids</i> , <b>2014</b> , 28, 1603-9	3.5	13
34	HIV-2 and HTLV-1 infections in Spain, a non-endemic region. <i>AIDS Reviews</i> , <b>2014</b> , 16, 152-9	1.5	7
33	Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. <i>Aids</i> , <b>2013</b> , 27, 2219-24	3.5	14
32	Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. <i>Aids</i> , <b>2013</b> , 27, 81-5	3.5	48
31	Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2013</b> , 68, 1994-2002	5.1	8
30	Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. <i>Antiviral Therapy</i> , <b>2013</b> , 18, 709-15	1.6	12
29	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. <i>Retrovirology</i> , <b>2012</b> , 9, 68	3.6	7
28	Trends in the prevalence and distribution of HTLV-1 and HTLV-2 infections in Spain. <i>Virology Journal</i> , <b>2012</b> , 9, 71	6.1	30

27	Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. <i>Clinical Infectious Diseases</i> , <b>2012</b> , 55, e1-4	11.6	22
26	HTLV infection among foreign pregnant women living in Spain. <i>Journal of Clinical Virology</i> , <b>2011</b> , 52, 119-125	14.5	17
25	Drug resistance mutations in patients infected with HIV-2 living in Spain. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2011</b> , 66, 1484-8	5.1	26
24	Automated extraction improves multiplex molecular detection of infection in septic patients. <i>PLoS ONE</i> , <b>2010</b> , 5, e13387	3.7	30
23	Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2010</b> , 65, 2502-4	5.1	17
22	Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey. <i>AIDS Research and Human Retroviruses</i> , <b>2010</b> , 26, 861-4	1.6	10
21	Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2009</b> , 63, 1006-10	5.1	54
20	Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain. <i>AIDS Research and Human Retroviruses</i> , <b>2009</b> , 25, 551-4	1.6	24
19	Septicemia caused by <i>Corynebacterium macginleyi</i> : a rare form of extraocular infection. <i>International Journal of Infectious Diseases</i> , <b>2008</b> , 12, 333-5	10.5	15
18	Implication of p38 mitogen-activated protein kinase isoforms (alpha, beta, gamma and delta) in CD4+ T-cell infection with human immunodeficiency virus type I. <i>Journal of General Virology</i> , <b>2008</b> , 89, 1661-1671	4.9	8
17	Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. <i>Journal of Clinical Microbiology</i> , <b>2008</b> , 46, 887-91	9.7	87
16	Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2008</b> , 48, 241-4	3.1	35
15	Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2007</b> , 59, 698-704	5.1	68
14	Hospital-based surveillance for HTLV-1/2 infections in Spain. <i>AIDS Research and Human Retroviruses</i> , <b>2007</b> , 23, 1075-7	1.6	5
13	High rate of infection with hepatitis C virus genotype 4 in a district of galicia, Spain. <i>Journal of Clinical Microbiology</i> , <b>2005</b> , 43, 5403-4	9.7	5
12	Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. <i>Journal of Medical Virology</i> , <b>2005</b> , 76, 268-70	19.7	16
11	Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. <i>Journal of Medical Virology</i> , <b>2005</b> , 77, 23-8	19.7	20
10	Hepatitis B virus genotyping based on cluster analysis of the region involved in lamivudine resistance. <i>Journal of Virological Methods</i> , <b>2004</b> , 115, 9-17	2.6	10

9	Total HCV core antigen assay. A new marker of HCV viremia and its application during treatment of chronic hepatitis C. <i>Journal of Virological Methods</i> , <b>2004</b> , 120, 173-7	2.6	11
8	Construction and characterization of a minimized version of the HIV-1 pNL4-3 plasmid and its application for pseudotyping HIV-1 vectors. <i>Molecular Biotechnology</i> , <b>2004</b> , 28, 87-95	3	2
7	Clinical impact of HTLV-1 infection in Spain: implications for public health and mandatory screening. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , <b>2002</b> , 30, 366-8	3.1	13
6	Infection with retroviruses other than HIV-1 in Spain: a retrospective analysis for HIV-2, HTLV-I, and/or HTLV-II. <i>HIV Clinical Trials</i> , <b>2002</b> , 3, 397-402		7
5	Prevalence of HTLV infection in pregnant women in Spain. <i>Sexually Transmitted Infections</i> , <b>2000</b> , 76, 366-70		18
4	Human immunodeficiency virus type 2 infection in Spain. The HIV-2 Spanish Study Group. <i>Intervirology</i> , <b>1999</b> , 42, 37-42	2.5	15
3	False-negative result in a microparticle enzyme immunoassay (MEIA) for the detection of antibodies to human immunodeficiency (HIV). <i>Scandinavian Journal of Infectious Diseases</i> , <b>1997</b> , 29, 643-4		
2	Epidemiology of HTLV-I infection in Spain. HTLV Spanish Study Group. <i>International Journal of Epidemiology</i> , <b>1996</b> , 25, 443-9	7.8	7
1	Interference between <i>Neisseria meningitidis</i> and PC-KLH induced anti-phosphorylcholine PFC responses in NZB/W autoimmune mice. <i>Microbiology and Immunology</i> , <b>1995</b> , 39, 491-7	2.7	1